Turnstone Biologics Corp. announced that members of its senior management team will participate in the following investor conferences.
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences:
| TD Cowen 44th Annual Global Health Care Conference | ||
| Type: | Presentation and one-on-one investor meetings | |
| Speaker: | Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer | |
| Date: | Wednesday, March 6, 2024 | |
| Presentation Time: | 2:10pm ET / 11:10am PT | |
| Location: | Boston, MA | |
| Leerink Partners Global Biopharma Conference 2024 | ||
| Type: Date: Location: | One-on-one investor meetings Wednesday, March 13, 2024 Miami, FL | |
A live webcast of the presentation may be accessed on the Events page of Turnstone’s Investor Relations website at https://ir.turnstonebio.com, where a replay will also be available for a limited period.
Institutional investors interested in meeting with members of Turnstone’s senior management team during the conferences may contact their respective representatives at TD Cowen and Leerink Partners for further information.
About Turnstone
Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s novel TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TIL, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com, and follow us on LinkedIn.
Contact
Ahmed Aneizi
Investor Relations
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com
